Alex Sokolovsky
Head of Investor Relations
Replay available
Corbion NV (OTC: CSNVY) Q1 2026 earnings conference call, held 2026-04-22. Replay captured from the company's public earnings webcast.

Head of Investor Relations
Chief Executive Officer
Chief Financial Officer
Analyst, KDC Securities
Analyst, Gulf Patriot Camp
Analyst, Barclays
Analyst, Kepler Chevre
Analyst, ING
Analyst
Welcome to the Corbyn Q1 2026 Results Conference Call. Following the opening remarks, there will be an opportunity for questions. Please note that this call will be recorded. I would now like to hand over to Mr. Alex Sokolovsky, Head of Investor Relations. Please go ahead, sir. Thank you, Operator. Good morning, and welcome to Corbyn's first quarter 2026 Interim Management Statement Conference Call. This morning, we published our Q1 2026 Results. The press release and presentation can be found on our website, www.corbion.com, Investor Relations, Financial Publications. Before we begin, please note that today's discussion will include forward-looking statements based on current expectations and assumptions. These statements involve risks and uncertainties that may cause actual results to differ materially from those expressed. Factors beyond our control, including market conditions, economic changes, and regulatory actions can impact outcome. Corbian does not undertake any obligation to update statements made in this call or contained in today's press release and presentation. For more details on our assumptions and estimates, please refer to our annual reports. This is Alex Sokolevsky, Head of IR, and with me on the call are Olivier Rigaud, Chief Executive Officer, and Peter Kazius, Chief Financial Officer. Now, I would like to hand the call over to Olivier. Olivier? Thank you, Alex. And good morning, everyone. And thank you for joining us today for Carbion's first quarter 2026 earnings call. Let me get straight to the point. As we are flying in February, the first quarter reflects phasing effects, primarily nutrition, and a very strong comparison base in functional ingredients and solutions. Against that backdrop, We deliver group sales of nearly 294 million and an ...